Brought to you by 
Metabolex signs deal with Ortho-McNeil for metabolic diseases
18 Jun 2019
Executive Summary
Metabolex and Johnson & Johnson's Ortho-McNeil division have agreed to develop compounds for various metabolic conditions, including Type II diabetes, obesity, and dyslipidemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com